NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
Clinical Trials
3 trialsNCT04351334 2024-09-19
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Pfizer
Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed